Literature DB >> 26183544

Structural development of stabilized helical peptides as inhibitors of estrogen receptor (ER)-mediated transcription.

Yosuke Demizu1, Takashi Misawa2, Takaya Nagakubo3, Yasunari Kanda4, Keiichiro Okuhira5, Yuko Sekino4, Mikihiko Naito5, Masaaki Kurihara6.   

Abstract

Three types of stabilized helical peptides containing disulfide bonds, C-C cross-linked side chains, or α,α-disubstituted amino acids (2-aminoisobutyric acid (Aib)) were designed and synthesized as inhibitors of estrogen receptor (ER)-coactivator interactions. Furthermore, heptaarginine (R7)-conjugated versions of the peptides were prepared, and their effects on ER-mediated transcription were evaluated at the cellular level (in ER-positive T47D cells). Among them, the R7-conjugated peptides 11 and 12 downregulated the mRNA expression of pS2 (an ER-mediated gene whose expression is upregulated by 17β-estradiol) by 95% (at a dose of 10 μM) and 87% (at a dose of 3 μM), respectively.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Estrogen receptor; Helical peptide; Protein–protein interaction; Transcriptional inhibitor

Mesh:

Substances:

Year:  2015        PMID: 26183544     DOI: 10.1016/j.bmc.2015.06.067

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  5 in total

Review 1.  Steroid receptor/coactivator binding inhibitors: An update.

Authors:  Kornelia J Skowron; Kenneth Booker; Changfeng Cheng; Simone Creed; Brian P David; Phillip R Lazzara; Amy Lian; Zamia Siddiqui; Thomas E Speltz; Terry W Moore
Journal:  Mol Cell Endocrinol       Date:  2019-06-01       Impact factor: 4.102

2.  Effect of TPA and HTLV-1 Tax on BRCA1 and ERE controlled genes expression.

Authors:  Azhar Jabareen; Aya Abu-Jaafar; Ammar Abou-Kandil; Mahmoud Huleihel
Journal:  Cell Cycle       Date:  2017-06-08       Impact factor: 4.534

3.  Differential effects of HTLV-1 Tax oncoprotein on the different estrogen-induced-ER α-mediated transcriptional activities.

Authors:  Ammar Abou-Kandil; Nora Eisa; Azhar Jabareen; Mahmoud Huleihel
Journal:  Cell Cycle       Date:  2016-07-15       Impact factor: 4.534

Review 4.  Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges.

Authors:  Chao Wang; Yujing Zhang; Tingting Zhang; Lingyu Shi; Zhongmin Geng; Dongming Xing
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

Review 5.  Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents.

Authors:  Chao Wang; Yujing Zhang; Lingyu Shi; Shanbo Yang; Jing Chang; Yingjie Zhong; Qian Li; Dongming Xing
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.